{"ticker": {"uuid": "51160eed-8652-4872-ab0c-4edc618dff1a", "symbol": "PGEN", "name": "Precigen Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4", "summary": "Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The company will host a conference call at 4:30 PM ET on that day to discuss the results. ", "url": "https://www.biospace.com/press-releases/precigen-to-announce-second-quarter-2026-financial-results-and-provide-business-updates-on-august-4", "source_name": "BioSpace", "published_at": "2026-07-21T18:40:32", "published_display": "21 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) to Release Q2 Financial Results and Discuss Business Progress", "summary": "Precigen (PGEN) will announce its Q2 financial results on August 4, 2026, and hold a conference call to discuss business developments, including the recent FDA approval of PAPZIMEOS. The company reported a significant revenue increase in Q1 2026 due to PAPZIMEOS sales, leading to", "url": "https://www.gurufocus.com/news/8969526/precigen-pgen-to-release-q2-financial-results-and-discuss-business-progress", "source_name": "GuruFocus", "published_at": "2026-07-21T16:40:32", "published_display": "21 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen sets 4:30 p.m. ET call for Aug. 4 business update", "summary": "Precigen (Nasdaq: PGEN) announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. A conference call to discuss the results will be held at 4:30 PM ET, and details are available on the company\u2019s investor website. T", "url": "https://www.stocktitan.net/news/PGEN/precigen-to-announce-second-quarter-2026-financial-results-and-8ebo6zxepy5e.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:40:32", "published_display": "21 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Precigen Inc Stocks", "summary": "This article provides a list of Exchange Traded Funds (ETFs) that hold shares of Precigen Inc. (PGEN), detailing each fund's market value, Precigen Inc. stock weight, issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs cover v", "url": "https://www.tradingview.com/symbols/BOATS-PGEN/etfs/", "source_name": "TradingView", "published_at": "2026-07-16T23:09:50", "published_display": "16 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Precigen (PGEN) Proxy Filing Summary", "summary": "Precigen's upcoming annual meeting on June 26, 2025, will address director elections, an increase in authorized common stock, approval of Series A Preferred Stock and Warrants issuance to Randal J. Kirk, auditor ratification, executive compensation, and amendments to equity incen", "url": "https://quartr.com/events/precigen-pgen-proxy-filing_3geAxzLW", "source_name": "Quartr", "published_at": "2026-07-16T08:41:02", "published_display": "16 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?", "summary": "Precigen CFO Harry Thomasian Jr. sold 200,000 shares for $1.1 million, reducing his direct ownership by 36% through a pre-arranged Rule 10b5-1 trading plan. This sale, occurring when shares hit a multi-year high, is not considered a red flag for investors due to the non-discretio", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3306510/what-does-the-sale-of-precigen-shares-worth-1-1-million-by-the-cfo-mean-for-investors/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T22:40:05", "published_display": "15 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative", "summary": "Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driv", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/precigen-pgen-in-focus-as-russell-removal-tests-its-underval", "source_name": "Simply Wall Street", "published_at": "2026-07-09T19:43:39", "published_display": "09 Jul 2026 19:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PGEN - Precigen Inc Options", "summary": "This article provides a detailed financial overview of Precigen Inc (PGEN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, such as EPS, sales growth, insider and institutional ownersh", "url": "https://finviz.com/stock?t=PGEN&ty=oc&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-07-03T12:39:46", "published_display": "03 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PRECIGEN, INC. SEC Filing", "summary": "This article announces an SEC Form 144 filing by Precigen, Inc. (PGEN), detailing a proposed sale of securities. The filing indicates a sale of 346,836 shares of common stock with an aggregate market value of $2,044,627.16 by an individual named Smithfield, acquired through a sto", "url": "https://www.stocktitan.net/sec-filings/PGEN/144-precigen-inc-sec-filing-722c6dc27457.html", "source_name": "Stock Titan", "published_at": "2026-07-03T07:11:30", "published_display": "03 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that an insider at Precigen sold shares totaling $1,113,143. This information is derived from the latest regulatory disclosure, indicating a significant insider transaction for the company.", "url": "https://www.moomoo.com/news/post/72382424/precigen-insider-sold-shares-worth-1113143-according-to-a-recent", "source_name": "Moomoo", "published_at": "2026-07-02T17:40:56", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Insider Sold Shares Worth $2,042,864, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/precigen-insider-sold-shares-worth-081308676.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:13:08+00:00", "published_display": "02 Jul 2026 08:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PGEN - Precigen Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings for Precigen Inc (PGEN), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It details current market capitalization, income, sales, EPS, and various valuation ratios, alongside re", "url": "https://finviz.com/stock?t=PGEN&b=2&p=d&ty=lf&page=31", "source_name": "Finviz", "published_at": "2026-07-02T04:40:54", "published_display": "02 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PRECIGEN, INC. Insider Trading Activity", "summary": "PRECIGEN, INC.'s President and CEO, Helen Sabzevari, conducted an exercise-and-sale transaction on June 29, 2026. She acquired 346,836 shares through stock options at $2.33 per share and subsequently sold them in open-market transactions at a weighted average price of $5.89, unde", "url": "https://www.stocktitan.net/sec-filings/PGEN/form-4-precigen-inc-insider-trading-activity-cd9059047c9d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:34:08", "published_display": "02 Jul 2026 04:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) COO sells 42,924 shares after option exercise", "summary": "Precigen's Chief Operating Officer, Rutul R. Shah, exercised stock options to acquire 42,924 shares at $2.33 per share and subsequently sold all those shares in an open-market transaction at $5.85 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading ", "url": "https://www.stocktitan.net/sec-filings/PGEN/form-4-precigen-inc-insider-trading-activity-154cbe105c3d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:08", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan", "summary": "Precigen's Chief Financial Officer, Harry Thomasian Jr., sold a total of 200,000 shares of Common Stock in open-market transactions on June 29 and July 1, 2026, under a pre-arranged 10b5-1 trading plan. The sales were executed at weighted average prices of $5.78 and $5.53 per sha", "url": "https://www.stocktitan.net/sec-filings/PGEN/form-4-precigen-inc-insider-trading-activity-bda1fe1053ba.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:08", "published_display": "01 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Precigen\u2019s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story?", "summary": "Precigen (PGEN) was removed from several Russell value indexes on June 27, 2026, which may lead to portfolio rebalancing by passive funds and shift its investor base towards more active investors. The company's investment narrative centers on the success of PAPZIMEOS and its abil", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/does-precigens-pgen-russell-value-index-exit-signal-a-shifti/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T17:10:41", "published_display": "01 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark", "summary": "Precigen, Inc. (PGEN) has been removed from the Russell 2000 Value Benchmark. This news follows a series of recent updates for the biopharmaceutical company, including winning FDA Orphan Drug Exclusivity for an airway disease treatment and reporting Q1 2026 earnings. The company,", "url": "https://www.marketscreener.com/news/precigen-inc-nasdaqgs-pgen-dropped-from-russell-2000-value-benchmark-ce7f5fdfd888f62c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:05:43", "published_display": "29 Jun 2026 15:05", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Inc Actuals & Estimates (BX:I5X)", "summary": "This article provides an overview of Precigen Inc (BX:I5X) financial actuals and estimates, including income statement, balance sheet, and cash flow data, along with analyst forecasts. It covers key financial metrics such as market capitalization, earnings per share, revenue, net", "url": "https://www.tradingview.com/symbols/BX-I5X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:39:37", "published_display": "26 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Shareholders Expand Incentive Plan, Reaffirm Governance", "summary": "Precigen shareholders approved an amendment to the company's 2023 Omnibus Incentive Plan, adding 7 million shares for equity awards, signaling continued support for equity-based compensation. They also re-elected directors, ratified auditors, and supported executive pay, reaffirm", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PGEN/pressreleases/3582/precigen-shareholders-expand-incentive-plan-reaffirm-governance/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T03:41:13", "published_display": "26 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Precigen, Inc. \u2013 NASDAQ:PGEN", "summary": "This article provides a financial data point for Precigen, Inc. (NASDAQ: PGEN), specifically its forward price-to-sales ratio. The page indicates that the market is currently closed, and no trades have been executed. It appears to be a data-only page from TradingView, offering a ", "url": "https://www.tradingview.com/symbols/NASDAQ-PGEN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:41:18", "published_display": "25 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) investors back 7M-share incentive pool and all board picks", "summary": "Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus Incentive Plan, increasing available shares for equity awards by 7 million. They also re-elected nine directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and passed a non-binding advi", "url": "https://www.stocktitan.net/sec-filings/PGEN/8-k-precigen-inc-reports-material-event-ef3b99063a40.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:11:10", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearfield And 2 Insider Picks For Strong Growth", "summary": "This article identifies three U.S. growth companies with high insider ownership: Clearfield (CLFD), BillionToOne (BLLN), and Precigen (PGEN). The U.S. market has seen a 2.3% decline recently, but is up 21% over the past year with 19% annual earnings growth forecasted. The article", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/clearfield-and-2-insider-picks-for-strong-growth/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T11:10:21", "published_display": "24 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS Therapy - What's Changed", "summary": "Precigen (PGEN) shares rose 12.1% following its PAPZIMEOS therapy receiving FDA orphan drug exclusivity, granting seven years of market protection for adult recurrent respiratory papillomatosis. This exclusivity strengthens the therapy's market position, especially with data show", "url": "https://www.sahmcapital.com/news/content/precigen-pgen-is-up-121-after-orphan-exclusivity-win-for-papzimeos-therapy-whats-changed-2026-06-23", "source_name": "Sahm", "published_at": "2026-06-24T07:11:10", "published_display": "24 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Ends 11.6% Higher \u2014 This FDA Approval Could Hold the Reason", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTVEtV3k3eElSUGxwQUppUVMySWZRRlBkZVI5TndTcWZqVEh3dlRZaGFOb1gzWTIwNHhQR3lEUDhidWFRZEx1UGtiSUZSVThpckhicVlnRDNZNVJxbC1ObWFyYlJRRFBpMzBRUFVwcS1aWXBsdWdwNnp5X240SjByemVBZVUwbVl0MW5pMw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win", "summary": "Precigen (PGEN) stock is under scrutiny after the FDA granted orphan drug exclusivity for PAPZIMEOS, which could significantly impact its commercial runway. Despite a strong recent share price performance, its high price-to-book ratio suggests it's overvalued based on current ass", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/precigen-pgen-stock-could-be-79-undervalued-after-fda-exclus", "source_name": "Simply Wall Street", "published_at": "2026-06-22T00:39:47", "published_display": "22 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS", "summary": "Precigen (PGEN) obtained FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine for adult recurrent respiratory papillomatosis (RRP), safeguarding its market exclusivity until August 2032. Developed with the AdenoVerse platform, PAPZIMEOS targets HPV 6 and 11, the causes", "url": "https://finance.yahoo.com/healthcare/articles/precigen-pgen-secures-fda-orphan-172827430.html", "source_name": "Market source", "published_at": "2026-06-20T19:40:04", "published_display": "20 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions", "summary": "Precigen, Inc. (PGEN) held its 2026 AGM where all proposals, including board elections, auditor ratification, executive compensation, and an incentive plan amendment, passed with overwhelming support. There were no shareholder questions or comments received during the meeting. Th", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3619628:0-pgen-all-proposals-including-board-elections-and-compensation-passed-overwhelmingly-without-shareholder-questions/", "source_name": "TradingView", "published_at": "2026-06-18T13:40:50", "published_display": "18 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Precigen Inc (PGEN) has an earnings forecast score of 7.33, placing it 103rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $8.50 for PGEN, with a \"Buy\" trend based on ratings from 3 analysts. The company's expected revenue for the next q", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pgen/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:50", "published_display": "18 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains a Buy on Precigen (PGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNUkg1TGprNlJDQ0JPR3BlQl85dHBNVjJ0TjMyN01zTzlHR1R3RWVNWFp2XzBabWwxbERIZHNWX1MyeUlEckVpMF9oZl83R2VyOFJiX0QxYnJyNXZFLXJXeUh6WGcyOFJ0eUVzcWpHVzE4TmZYaHNiUkJxc1JpaHdNV1J1eGJnVWZrdXFqS0tNRnU?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Wins FDA Orphan Drug Exclusivity for Airway Disease Treatment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/precigen-wins-fda-orphan-drug-113601635.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:36:01+00:00", "published_display": "15 Jun 2026 11:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/precigen-gains-advantage-papzimeos-granted-104000120.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-15T10:40:00+00:00", "published_display": "15 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQc1M5UGlrQ05SWWl0XzJWeTlLTnBGRjlQMm1iMnFITzVYdEFpc1lOQWJ2M0kxRUEyblk3NzRwTzh1LWJQZWZEVWlveWU4Z3A0RzJaT2hpOHdacTY0Q0J6STJZaXl3ak1KUDlsbkgtcXlDd1BTSVVKak9FV1VuSzJrUDlqclhSNHdFdU55enFQWG9lNk9NS3hnTHNMWEhSOF8tUUE?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdUp2QmdNSGtEWlBBaXBUTEFEY2t3MTlQQkpuZVh2bVZzckVmSnJqcUUwVlJYeE5ydmZjWjNRckVVMXlLVGNEdnoyM3lJTURDRkZoU3BWcDNFZzZHQXc1X0ZUdWp5dWVWUzUzbUctaG9WclRqSWxYX3RCbWVsNmxXdFIzZWRwLUJyNXNFMGFpVkhjTHdyTEJFd3VYUFVLZlY3MUh6WlROV0Q3b0JVRThldVh1OGU1c1kxU2wxMA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Precigen Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQSWFtVzJJQ2hxOTN2NzlKTkwxY3RubHlLQkplMlFUck5ES3BmX1hEWnptaDM4YTMzTmY4dEFqbmgyRUdYMDA5VUxCRUdfZnU2cm5YU0h2WGF6ODh4WFFiXzBra0JkN1QzcHJWOVJCVjFIVFFDUVdRUGVFZEZsRi1EajFtNmhrQ1RDbXdHQ2ZNNUFwYnpMOWhFOVBmTjN1QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen chief legal officer Lehr sells $127,011 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVVFTSzFOVHNhRGxvSjdGT3BEMmg3Y3VuWGtOdjBvN1JGVEc1elFkYTNQSXlETUpWZ2Y3a05OWjdpRlczQmlXWWJFRmRtbG1OM2VQOWxWd0IwV2FqVkxKVS1QWXFldVIwTVdaVW5JY0lCM1M2UkRDMktvbUhaWEpMZjVHOFFiTGdHVDhNWlpVS2pmNjNJZ0VDbDJJWWQ4Y0dFZU5EU0RDQnhvblBodEoyaWxpdXpjd2I0UDlldg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen CEO Helen Sabzevari sells $519,930 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPYXBwaUJpNFE2WjdGS3lBb2VIam9ISlJlcXZWX1RxRXhuLWlaR3ZYZnNRTnNUTHV6aUdrLVRYVjZnN1ZlRGQtTE53VHdickhEU0J0UzN2Z3F0Z2pFVkNRbHVnVTd2RkZGbXhBSlE1RHU1bzBGUmctRHI4UldybkNoZ242ZENBQ3NPMVMwSUp6TkZZMXV2TVQ5WFZKMU9xRktXU0RsSmxOMk5nNGFRZE5yYjVOYzQ0UHA0UkxhWlpVY2k?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) CFO gains 87,500 shares from RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcG1GamZtMEtSbmwxaER0YjJBSktMbDF4U1hyMElKQU9RNS0xaUxIS21TdG8tYTNGRzBaQzl1MEhYZExLYU1zUGEwWjVmd3JhVlVrai00X1FTTmRRbDZQanlJS3gyYUR1VXlUV3NXUE02b2NXU09VeHUyanU5Nld4Q05zTm00dG9VR3NXWFhScFM3cjZCcTBUbk1CNFY2QzVKdEh6LTVOdUtkdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen CEO set for J.P. Morgan and Goldman Sachs healthcare fireside chats", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRFUyY29JUEZSeTd1VVdoeWFPV3BZOWFXeWhaclRhQkxUaHZSX2R0dzJmbjR5aVFJcmJiRlQydWNUMjBaa3VUVEQ2ZDFxanFXYTVKZlJESXZabzhnZGkzaW9qWk9HR3EwRFkzTW5qU2xpQmdIZUV5WlpZWWZER0doZEtSeEx2VEUyYjhrUkc2RzJKMmdDQmlMN2ZRTGFUUFNpcWRoaGd0ZmNaaUZWVDNxcHNYY1Q2dzZLcjJpU2FTZWw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN): The Best Penny Stock to Buy for Long Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPWXU1N1VCTjZDdnV6SFBLd1Z1UlA3WkNQU3ZQZmdrNFRDTVFUeW5ZYlRCR1B3N2E4U3B0MUtzWkEzWXlIQThsZG1aaHFSMldPeXl1aVhRZVZkaW9VbFJZTldyUHNiZFpDNTE5Sy03X2NXcXU3ZkVQcFZfa3RrU0pYTVVLR09RbGh1WGNZYThZYjRaMGo4T0d1ZDQ1Yw?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQmtVTkJITFBIRkxtZWR0NlVCc2JMeW1GeF9Tb2FRR3RkYW9UZUt4bnltVEs0SVU2VTA0RklWODJBTEFXc1pNdkswUEcta25ZVU52TXhJeWhxYUdhb1pJV3lWb1NnU2t5STd5OXBSejA0clJpaXRkYUs1SWt0NFFQTlVFUzBBVWtIQ05hMUItT2lpNC1XWDZ2d21LbzNBR1k?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Precigen Reports First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNNTE3Si1QM3dEa2hnTzlOUVhiVjhVWmxoTVdRb2wyWHdRckJnSm9CdjJBYWd1amtHbnBPOUpCbUR5U0VWWXNVLWNFRnBrZW5FU214REJjOGRWVWdrWWJmM0pwNXlUcGp6MUV6R2E2UlNGaHZaaDBMRk1UWmdvb3BrWWYwdlN1alVTRm04clFtRFNyTVMxTWlTU0VtNzdQRktfT1k4NEdmelM2RTdZbmNuZ1oyVWdwY2dZbDVIU1RWdDdOeGJYYmY0MF9R?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOSGVEX3ZMbERIR2dEQ1ZxdllscUxEV3FsdWo3aXFwc1U3cnZIZ2dqbDk2cUE3QlR5WC0yQnhlY1YwYklQdDI2LXhIR0hNbGNYSnFhdllCUVI1Wi1jV2ZXbi04TVgxaFBMNUZ5NEJNNXJ2UE9EcWhnb1FITnM2NTUyY0tROC1PTldZcGNKV2R5cF81Uy1maGduNQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "May 13 at 4:30 ET: Precigen pairs Q1 results with business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQSW90TmNhODFMOWlVWVVVWmRpVGFTYUlmS1d0QnJabFFLLS1IVTQ5cFZGeDN2SXdnaDRZdzRQTzlOaWNXd3NvaFdhSkhraV9jSG1HdHliT0RYelk5QUZoaHZkVmNqRE45emdRODZnZUt4RnRaRXN4SHFwSTdpSFh3a0dRWUZvbEhXSkpBaC1iSmNpSmUtR2RHbm1weV9ob3JxSUlsWlYwRXJOZTJ0QXZvZjZlN3luQUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYnRuX3hVRzB6Uy15M3RWYmNZQi1ZVXZMVUFXalFvTEV0U2J0TV9nekdUNjM3ck9FbFVhbTFxNnNCdUpCcTdkQlItQ3hEQVF1dFVCaVZyUlhoazAzNXJYblBrS2ZWcktSUTRxcnJEdlhraTROdHB4cC1uZ1VEYjlzZUV4b3ZmUFFwMXB5UDMyc0xhX0xtN191Yg?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOYzNLbVhUQXU1d0Q1M2ZkWVhUM2Y4aUVmQ2F2YWNVS2NVbVFBQVJWblU5aWRzbUlhMzBmc1psU0w0d3NkenJUVklIZWJnUVg4M1lJX0I5SWdaS191SUtwSkZqY0s0OTZwUjNUZXIxdTdNSnFiRzBIbmMtV2ROel9nYW9vSUVCcHFRc296WTgwN1Z1bU9VcUhscFR2WTR3eGl4VUVpVg?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Bullish on \u200bPrecigen (PGEN) As the Company Transitions to Commercial Stage", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWWQ2VExVQnZFUVRHenEtQzJmb2s3XzBYVVZoUjFLellUUTZwMmdTaUdxWUNFa19xcWdhMm53eVZCcTFpbXZoVlAyeFpjei02MEVjanFtV2tGZmdhVHFXbUl4MGpzeG81Z1hwejBvWTdoUFV2ZVR2ZWN2OEtKRktYX09nYnBNOTNienZxdTNxckVxclhaWmtiQXBZY3pUeHM?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQemFtZ0xralJXNHJXX3dPUE54VThPS3BETUNiVVlPc2ExcUVCb2NVVGlXVTkwZ3FLeG02SHQ2OTlnNzlMWkVIdFR0ZDNTUTFTcWg3cDRfRGZ5SXlQd2hZbTljRzdCYU8yLU5GLUJ3dkxfVjBBS2dWMG9DdGZ3UDFWLTk2dy12bi0tNmdRY2RoTjJtNXpqUVRoYlVjZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Reports Full Year 2025 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOQXBLckpkQXFHbXlQY0kyekFaVHhDOF9Da3VMNTdta2RfbjJoelk3UFVIYjl4dXM0RHdCYWE2NkRQcFpLcEdkOC1Xb0xYTWRvNk5lVkU0T1J3Y2IzLXppNHNTUUpoUkkzSm9iUk5ZY1dYRXI2ZVl0bFRadjdhTTNtT0Z3dTBTd3BZa1k0ODhBakFwV2VCS2JQTVRaaUswbnhOVURFdS1qX3IwV0RIN3BEUDBPcHM3dlFSc1c1RTRBVE9GQThn?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPY1l5RzNXSFJDY01aLWdEb3EtWFp1NV9kNmhtdXNmUGJRUWN6Rjl4TURCSEVOZmU5MFFveVFQNnBJYzhkbHpGVUpURnFFMnhPdFJKTUN4NXBYeTBLdjJMdHdwX0tQOFBYcUtGNGJxc0dOVFhHcnMtQkhOZFlYcXJhX243cm9WRlJtVGd5MXRhN2lyazR6WnNaemdSY1JGUC1LcXYzTjZkamtMcjZfMFRGVUxjeUJtMGpLVjRuTTlHRDN1d2JXRzc4c9IBzgFBVV95cUxPOGMzNWJtWTRpSlB2RzVaN19jd1lXdWtQMUlBZ2l0ZWxwbHFobVMzb2xyaThITXVPdEk0cUFicFJuYXlxaVB4Y0gwbURLbncwcTFYTUl3SEZLYkVGV2JxMnZ5MjRBTTlCTHNaZk1EbmdyQi02VklZMExPM2JaWHQwOVZjM3gwV0pzdEJWc0hHeWtKWVBXVEFfc19Cd3MtVXNTZkZ0ZjNZaVFZeE5TSjJ1REw5NnljY0NEUlhReS05Q1YwWEVCQmk0aGpCcV9FUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4", "summary": "Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The company will host a conference call at 4:30 PM ET on that day to discuss the results. ", "url": "https://www.biospace.com/press-releases/precigen-to-announce-second-quarter-2026-financial-results-and-provide-business-updates-on-august-4", "source_name": "BioSpace", "published_at": "2026-07-21T18:40:32", "published_display": "21 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) to Release Q2 Financial Results and Discuss Business Progress", "summary": "Precigen (PGEN) will announce its Q2 financial results on August 4, 2026, and hold a conference call to discuss business developments, including the recent FDA approval of PAPZIMEOS. The company reported a significant revenue increase in Q1 2026 due to PAPZIMEOS sales, leading to", "url": "https://www.gurufocus.com/news/8969526/precigen-pgen-to-release-q2-financial-results-and-discuss-business-progress", "source_name": "GuruFocus", "published_at": "2026-07-21T16:40:32", "published_display": "21 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen sets 4:30 p.m. ET call for Aug. 4 business update", "summary": "Precigen (Nasdaq: PGEN) announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. A conference call to discuss the results will be held at 4:30 PM ET, and details are available on the company\u2019s investor website. T", "url": "https://www.stocktitan.net/news/PGEN/precigen-to-announce-second-quarter-2026-financial-results-and-8ebo6zxepy5e.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:40:32", "published_display": "21 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Precigen Inc Stocks", "summary": "This article provides a list of Exchange Traded Funds (ETFs) that hold shares of Precigen Inc. (PGEN), detailing each fund's market value, Precigen Inc. stock weight, issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs cover v", "url": "https://www.tradingview.com/symbols/BOATS-PGEN/etfs/", "source_name": "TradingView", "published_at": "2026-07-16T23:09:50", "published_display": "16 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Proxy Filing Summary", "summary": "Precigen's upcoming annual meeting on June 26, 2025, will address director elections, an increase in authorized common stock, approval of Series A Preferred Stock and Warrants issuance to Randal J. Kirk, auditor ratification, executive compensation, and amendments to equity incen", "url": "https://quartr.com/events/precigen-pgen-proxy-filing_3geAxzLW", "source_name": "Quartr", "published_at": "2026-07-16T08:41:02", "published_display": "16 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?", "summary": "Precigen CFO Harry Thomasian Jr. sold 200,000 shares for $1.1 million, reducing his direct ownership by 36% through a pre-arranged Rule 10b5-1 trading plan. This sale, occurring when shares hit a multi-year high, is not considered a red flag for investors due to the non-discretio", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3306510/what-does-the-sale-of-precigen-shares-worth-1-1-million-by-the-cfo-mean-for-investors/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T22:40:05", "published_display": "15 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative", "summary": "Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driv", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/precigen-pgen-in-focus-as-russell-removal-tests-its-underval", "source_name": "Simply Wall Street", "published_at": "2026-07-09T19:43:39", "published_display": "09 Jul 2026 19:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PGEN - Precigen Inc Options", "summary": "This article provides a detailed financial overview of Precigen Inc (PGEN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, such as EPS, sales growth, insider and institutional ownersh", "url": "https://finviz.com/stock?t=PGEN&ty=oc&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-07-03T12:39:46", "published_display": "03 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PRECIGEN, INC. SEC Filing", "summary": "This article announces an SEC Form 144 filing by Precigen, Inc. (PGEN), detailing a proposed sale of securities. The filing indicates a sale of 346,836 shares of common stock with an aggregate market value of $2,044,627.16 by an individual named Smithfield, acquired through a sto", "url": "https://www.stocktitan.net/sec-filings/PGEN/144-precigen-inc-sec-filing-722c6dc27457.html", "source_name": "Stock Titan", "published_at": "2026-07-03T07:11:30", "published_display": "03 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that an insider at Precigen sold shares totaling $1,113,143. This information is derived from the latest regulatory disclosure, indicating a significant insider transaction for the company.", "url": "https://www.moomoo.com/news/post/72382424/precigen-insider-sold-shares-worth-1113143-according-to-a-recent", "source_name": "Moomoo", "published_at": "2026-07-02T17:40:56", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Insider Sold Shares Worth $2,042,864, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/precigen-insider-sold-shares-worth-081308676.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:13:08+00:00", "published_display": "02 Jul 2026 08:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PGEN - Precigen Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings for Precigen Inc (PGEN), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It details current market capitalization, income, sales, EPS, and various valuation ratios, alongside re", "url": "https://finviz.com/stock?t=PGEN&b=2&p=d&ty=lf&page=31", "source_name": "Finviz", "published_at": "2026-07-02T04:40:54", "published_display": "02 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PRECIGEN, INC. Insider Trading Activity", "summary": "PRECIGEN, INC.'s President and CEO, Helen Sabzevari, conducted an exercise-and-sale transaction on June 29, 2026. She acquired 346,836 shares through stock options at $2.33 per share and subsequently sold them in open-market transactions at a weighted average price of $5.89, unde", "url": "https://www.stocktitan.net/sec-filings/PGEN/form-4-precigen-inc-insider-trading-activity-cd9059047c9d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:34:08", "published_display": "02 Jul 2026 04:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) COO sells 42,924 shares after option exercise", "summary": "Precigen's Chief Operating Officer, Rutul R. Shah, exercised stock options to acquire 42,924 shares at $2.33 per share and subsequently sold all those shares in an open-market transaction at $5.85 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading ", "url": "https://www.stocktitan.net/sec-filings/PGEN/form-4-precigen-inc-insider-trading-activity-154cbe105c3d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:08", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan", "summary": "Precigen's Chief Financial Officer, Harry Thomasian Jr., sold a total of 200,000 shares of Common Stock in open-market transactions on June 29 and July 1, 2026, under a pre-arranged 10b5-1 trading plan. The sales were executed at weighted average prices of $5.78 and $5.53 per sha", "url": "https://www.stocktitan.net/sec-filings/PGEN/form-4-precigen-inc-insider-trading-activity-bda1fe1053ba.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:08", "published_display": "01 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Precigen\u2019s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story?", "summary": "Precigen (PGEN) was removed from several Russell value indexes on June 27, 2026, which may lead to portfolio rebalancing by passive funds and shift its investor base towards more active investors. The company's investment narrative centers on the success of PAPZIMEOS and its abil", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/does-precigens-pgen-russell-value-index-exit-signal-a-shifti/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T17:10:41", "published_display": "01 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark", "summary": "Precigen, Inc. (PGEN) has been removed from the Russell 2000 Value Benchmark. This news follows a series of recent updates for the biopharmaceutical company, including winning FDA Orphan Drug Exclusivity for an airway disease treatment and reporting Q1 2026 earnings. The company,", "url": "https://www.marketscreener.com/news/precigen-inc-nasdaqgs-pgen-dropped-from-russell-2000-value-benchmark-ce7f5fdfd888f62c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:05:43", "published_display": "29 Jun 2026 15:05", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Inc Actuals & Estimates (BX:I5X)", "summary": "This article provides an overview of Precigen Inc (BX:I5X) financial actuals and estimates, including income statement, balance sheet, and cash flow data, along with analyst forecasts. It covers key financial metrics such as market capitalization, earnings per share, revenue, net", "url": "https://www.tradingview.com/symbols/BX-I5X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:39:37", "published_display": "26 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Shareholders Expand Incentive Plan, Reaffirm Governance", "summary": "Precigen shareholders approved an amendment to the company's 2023 Omnibus Incentive Plan, adding 7 million shares for equity awards, signaling continued support for equity-based compensation. They also re-elected directors, ratified auditors, and supported executive pay, reaffirm", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PGEN/pressreleases/3582/precigen-shareholders-expand-incentive-plan-reaffirm-governance/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T03:41:13", "published_display": "26 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Precigen, Inc. \u2013 NASDAQ:PGEN", "summary": "This article provides a financial data point for Precigen, Inc. (NASDAQ: PGEN), specifically its forward price-to-sales ratio. The page indicates that the market is currently closed, and no trades have been executed. It appears to be a data-only page from TradingView, offering a ", "url": "https://www.tradingview.com/symbols/NASDAQ-PGEN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:41:18", "published_display": "25 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) investors back 7M-share incentive pool and all board picks", "summary": "Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus Incentive Plan, increasing available shares for equity awards by 7 million. They also re-elected nine directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and passed a non-binding advi", "url": "https://www.stocktitan.net/sec-filings/PGEN/8-k-precigen-inc-reports-material-event-ef3b99063a40.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:11:10", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearfield And 2 Insider Picks For Strong Growth", "summary": "This article identifies three U.S. growth companies with high insider ownership: Clearfield (CLFD), BillionToOne (BLLN), and Precigen (PGEN). The U.S. market has seen a 2.3% decline recently, but is up 21% over the past year with 19% annual earnings growth forecasted. The article", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/clearfield-and-2-insider-picks-for-strong-growth/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-24T11:10:21", "published_display": "24 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS Therapy - What's Changed", "summary": "Precigen (PGEN) shares rose 12.1% following its PAPZIMEOS therapy receiving FDA orphan drug exclusivity, granting seven years of market protection for adult recurrent respiratory papillomatosis. This exclusivity strengthens the therapy's market position, especially with data show", "url": "https://www.sahmcapital.com/news/content/precigen-pgen-is-up-121-after-orphan-exclusivity-win-for-papzimeos-therapy-whats-changed-2026-06-23", "source_name": "Sahm", "published_at": "2026-06-24T07:11:10", "published_display": "24 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Ends 11.6% Higher \u2014 This FDA Approval Could Hold the Reason", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTVEtV3k3eElSUGxwQUppUVMySWZRRlBkZVI5TndTcWZqVEh3dlRZaGFOb1gzWTIwNHhQR3lEUDhidWFRZEx1UGtiSUZSVThpckhicVlnRDNZNVJxbC1ObWFyYlJRRFBpMzBRUFVwcS1aWXBsdWdwNnp5X240SjByemVBZVUwbVl0MW5pMw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win", "summary": "Precigen (PGEN) stock is under scrutiny after the FDA granted orphan drug exclusivity for PAPZIMEOS, which could significantly impact its commercial runway. Despite a strong recent share price performance, its high price-to-book ratio suggests it's overvalued based on current ass", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pgen/precigen/news/precigen-pgen-stock-could-be-79-undervalued-after-fda-exclus", "source_name": "Simply Wall Street", "published_at": "2026-06-22T00:39:47", "published_display": "22 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS", "summary": "Precigen (PGEN) obtained FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine for adult recurrent respiratory papillomatosis (RRP), safeguarding its market exclusivity until August 2032. Developed with the AdenoVerse platform, PAPZIMEOS targets HPV 6 and 11, the causes", "url": "https://finance.yahoo.com/healthcare/articles/precigen-pgen-secures-fda-orphan-172827430.html", "source_name": "Market source", "published_at": "2026-06-20T19:40:04", "published_display": "20 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions", "summary": "Precigen, Inc. (PGEN) held its 2026 AGM where all proposals, including board elections, auditor ratification, executive compensation, and an incentive plan amendment, passed with overwhelming support. There were no shareholder questions or comments received during the meeting. Th", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3619628:0-pgen-all-proposals-including-board-elections-and-compensation-passed-overwhelmingly-without-shareholder-questions/", "source_name": "TradingView", "published_at": "2026-06-18T13:40:50", "published_display": "18 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Precigen Inc (PGEN) has an earnings forecast score of 7.33, placing it 103rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $8.50 for PGEN, with a \"Buy\" trend based on ratings from 3 analysts. The company's expected revenue for the next q", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pgen/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:50", "published_display": "18 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains a Buy on Precigen (PGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNUkg1TGprNlJDQ0JPR3BlQl85dHBNVjJ0TjMyN01zTzlHR1R3RWVNWFp2XzBabWwxbERIZHNWX1MyeUlEckVpMF9oZl83R2VyOFJiX0QxYnJyNXZFLXJXeUh6WGcyOFJ0eUVzcWpHVzE4TmZYaHNiUkJxc1JpaHdNV1J1eGJnVWZrdXFqS0tNRnU?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Wins FDA Orphan Drug Exclusivity for Airway Disease Treatment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/precigen-wins-fda-orphan-drug-113601635.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:36:01+00:00", "published_display": "15 Jun 2026 11:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/precigen-gains-advantage-papzimeos-granted-104000120.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-15T10:40:00+00:00", "published_display": "15 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQc1M5UGlrQ05SWWl0XzJWeTlLTnBGRjlQMm1iMnFITzVYdEFpc1lOQWJ2M0kxRUEyblk3NzRwTzh1LWJQZWZEVWlveWU4Z3A0RzJaT2hpOHdacTY0Q0J6STJZaXl3ak1KUDlsbkgtcXlDd1BTSVVKak9FV1VuSzJrUDlqclhSNHdFdU55enFQWG9lNk9NS3hnTHNMWEhSOF8tUUE?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdUp2QmdNSGtEWlBBaXBUTEFEY2t3MTlQQkpuZVh2bVZzckVmSnJqcUUwVlJYeE5ydmZjWjNRckVVMXlLVGNEdnoyM3lJTURDRkZoU3BWcDNFZzZHQXc1X0ZUdWp5dWVWUzUzbUctaG9WclRqSWxYX3RCbWVsNmxXdFIzZWRwLUJyNXNFMGFpVkhjTHdyTEJFd3VYUFVLZlY3MUh6WlROV0Q3b0JVRThldVh1OGU1c1kxU2wxMA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Precigen Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQSWFtVzJJQ2hxOTN2NzlKTkwxY3RubHlLQkplMlFUck5ES3BmX1hEWnptaDM4YTMzTmY4dEFqbmgyRUdYMDA5VUxCRUdfZnU2cm5YU0h2WGF6ODh4WFFiXzBra0JkN1QzcHJWOVJCVjFIVFFDUVdRUGVFZEZsRi1EajFtNmhrQ1RDbXdHQ2ZNNUFwYnpMOWhFOVBmTjN1QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen chief legal officer Lehr sells $127,011 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVVFTSzFOVHNhRGxvSjdGT3BEMmg3Y3VuWGtOdjBvN1JGVEc1elFkYTNQSXlETUpWZ2Y3a05OWjdpRlczQmlXWWJFRmRtbG1OM2VQOWxWd0IwV2FqVkxKVS1QWXFldVIwTVdaVW5JY0lCM1M2UkRDMktvbUhaWEpMZjVHOFFiTGdHVDhNWlpVS2pmNjNJZ0VDbDJJWWQ4Y0dFZU5EU0RDQnhvblBodEoyaWxpdXpjd2I0UDlldg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen CEO Helen Sabzevari sells $519,930 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPYXBwaUJpNFE2WjdGS3lBb2VIam9ISlJlcXZWX1RxRXhuLWlaR3ZYZnNRTnNUTHV6aUdrLVRYVjZnN1ZlRGQtTE53VHdickhEU0J0UzN2Z3F0Z2pFVkNRbHVnVTd2RkZGbXhBSlE1RHU1bzBGUmctRHI4UldybkNoZ242ZENBQ3NPMVMwSUp6TkZZMXV2TVQ5WFZKMU9xRktXU0RsSmxOMk5nNGFRZE5yYjVOYzQ0UHA0UkxhWlpVY2k?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN) CFO gains 87,500 shares from RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcG1GamZtMEtSbmwxaER0YjJBSktMbDF4U1hyMElKQU9RNS0xaUxIS21TdG8tYTNGRzBaQzl1MEhYZExLYU1zUGEwWjVmd3JhVlVrai00X1FTTmRRbDZQanlJS3gyYUR1VXlUV3NXUE02b2NXU09VeHUyanU5Nld4Q05zTm00dG9VR3NXWFhScFM3cjZCcTBUbk1CNFY2QzVKdEh6LTVOdUtkdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen CEO set for J.P. Morgan and Goldman Sachs healthcare fireside chats", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRFUyY29JUEZSeTd1VVdoeWFPV3BZOWFXeWhaclRhQkxUaHZSX2R0dzJmbjR5aVFJcmJiRlQydWNUMjBaa3VUVEQ2ZDFxanFXYTVKZlJESXZabzhnZGkzaW9qWk9HR3EwRFkzTW5qU2xpQmdIZUV5WlpZWWZER0doZEtSeEx2VEUyYjhrUkc2RzJKMmdDQmlMN2ZRTGFUUFNpcWRoaGd0ZmNaaUZWVDNxcHNYY1Q2dzZLcjJpU2FTZWw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen (PGEN): The Best Penny Stock to Buy for Long Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPWXU1N1VCTjZDdnV6SFBLd1Z1UlA3WkNQU3ZQZmdrNFRDTVFUeW5ZYlRCR1B3N2E4U3B0MUtzWkEzWXlIQThsZG1aaHFSMldPeXl1aVhRZVZkaW9VbFJZTldyUHNiZFpDNTE5Sy03X2NXcXU3ZkVQcFZfa3RrU0pYTVVLR09RbGh1WGNZYThZYjRaMGo4T0d1ZDQ1Yw?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQmtVTkJITFBIRkxtZWR0NlVCc2JMeW1GeF9Tb2FRR3RkYW9UZUt4bnltVEs0SVU2VTA0RklWODJBTEFXc1pNdkswUEcta25ZVU52TXhJeWhxYUdhb1pJV3lWb1NnU2t5STd5OXBSejA0clJpaXRkYUs1SWt0NFFQTlVFUzBBVWtIQ05hMUItT2lpNC1XWDZ2d21LbzNBR1k?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Reports First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNNTE3Si1QM3dEa2hnTzlOUVhiVjhVWmxoTVdRb2wyWHdRckJnSm9CdjJBYWd1amtHbnBPOUpCbUR5U0VWWXNVLWNFRnBrZW5FU214REJjOGRWVWdrWWJmM0pwNXlUcGp6MUV6R2E2UlNGaHZaaDBMRk1UWmdvb3BrWWYwdlN1alVTRm04clFtRFNyTVMxTWlTU0VtNzdQRktfT1k4NEdmelM2RTdZbmNuZ1oyVWdwY2dZbDVIU1RWdDdOeGJYYmY0MF9R?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOSGVEX3ZMbERIR2dEQ1ZxdllscUxEV3FsdWo3aXFwc1U3cnZIZ2dqbDk2cUE3QlR5WC0yQnhlY1YwYklQdDI2LXhIR0hNbGNYSnFhdllCUVI1Wi1jV2ZXbi04TVgxaFBMNUZ5NEJNNXJ2UE9EcWhnb1FITnM2NTUyY0tROC1PTldZcGNKV2R5cF81Uy1maGduNQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "May 13 at 4:30 ET: Precigen pairs Q1 results with business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQSW90TmNhODFMOWlVWVVVWmRpVGFTYUlmS1d0QnJabFFLLS1IVTQ5cFZGeDN2SXdnaDRZdzRQTzlOaWNXd3NvaFdhSkhraV9jSG1HdHliT0RYelk5QUZoaHZkVmNqRE45emdRODZnZUt4RnRaRXN4SHFwSTdpSFh3a0dRWUZvbEhXSkpBaC1iSmNpSmUtR2RHbm1weV9ob3JxSUlsWlYwRXJOZTJ0QXZvZjZlN3luQUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYnRuX3hVRzB6Uy15M3RWYmNZQi1ZVXZMVUFXalFvTEV0U2J0TV9nekdUNjM3ck9FbFVhbTFxNnNCdUpCcTdkQlItQ3hEQVF1dFVCaVZyUlhoazAzNXJYblBrS2ZWcktSUTRxcnJEdlhraTROdHB4cC1uZ1VEYjlzZUV4b3ZmUFFwMXB5UDMyc0xhX0xtN191Yg?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOYzNLbVhUQXU1d0Q1M2ZkWVhUM2Y4aUVmQ2F2YWNVS2NVbVFBQVJWblU5aWRzbUlhMzBmc1psU0w0d3NkenJUVklIZWJnUVg4M1lJX0I5SWdaS191SUtwSkZqY0s0OTZwUjNUZXIxdTdNSnFiRzBIbmMtV2ROel9nYW9vSUVCcHFRc296WTgwN1Z1bU9VcUhscFR2WTR3eGl4VUVpVg?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Bullish on \u200bPrecigen (PGEN) As the Company Transitions to Commercial Stage", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWWQ2VExVQnZFUVRHenEtQzJmb2s3XzBYVVZoUjFLellUUTZwMmdTaUdxWUNFa19xcWdhMm53eVZCcTFpbXZoVlAyeFpjei02MEVjanFtV2tGZmdhVHFXbUl4MGpzeG81Z1hwejBvWTdoUFV2ZVR2ZWN2OEtKRktYX09nYnBNOTNienZxdTNxckVxclhaWmtiQXBZY3pUeHM?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQemFtZ0xralJXNHJXX3dPUE54VThPS3BETUNiVVlPc2ExcUVCb2NVVGlXVTkwZ3FLeG02SHQ2OTlnNzlMWkVIdFR0ZDNTUTFTcWg3cDRfRGZ5SXlQd2hZbTljRzdCYU8yLU5GLUJ3dkxfVjBBS2dWMG9DdGZ3UDFWLTk2dy12bi0tNmdRY2RoTjJtNXpqUVRoYlVjZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen Reports Full Year 2025 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOQXBLckpkQXFHbXlQY0kyekFaVHhDOF9Da3VMNTdta2RfbjJoelk3UFVIYjl4dXM0RHdCYWE2NkRQcFpLcEdkOC1Xb0xYTWRvNk5lVkU0T1J3Y2IzLXppNHNTUUpoUkkzSm9iUk5ZY1dYRXI2ZVl0bFRadjdhTTNtT0Z3dTBTd3BZa1k0ODhBakFwV2VCS2JQTVRaaUswbnhOVURFdS1qX3IwV0RIN3BEUDBPcHM3dlFSc1c1RTRBVE9GQThn?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 63, "sentiment_summary": {"positive": 22, "negative": 6, "neutral": 35, "score": 54, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 11.41, "count": 23}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 4.95, "latest_week": "2026-07-17", "one_week_move": -7.0, "four_week_move": 2.7, "twelve_week_move": 19.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.045776, "market_dynamics_buy_signal": false, "relative_strength": 11.422467, "fair_value_gap": 121.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.9508, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.0% over one week, +2.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 18}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Simply Wall Street", "count": 4}, {"label": "The Globe and Mail", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 23}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.0% over one week, +2.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4"}], "updated_at": "2026-07-22T22:34:26.912015+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}